Progesterone Receptor Regulation of Interferon Signaling in Breast Cancer
Progesterone Receptor Regulation of Interferon Signaling in Breast Cancer
批准号:
9753704
负责人:
Katherine Rose Walter
金额:
$3.41万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-01 至 2020-05-31
关键词:
AddressAffectBiological AssayCancer EtiologyCessation of lifeChromatinClinical TrialsCo-ImmunoprecipitationsDNADNA BindingDataDetectionDevelopmentDiagnosisDiseaseDown-RegulationEstrogen ReceptorsEstrogensFamily memberGene ExpressionGene ProteinsGenesGenetic TranscriptionGenomicsHistocompatibilityHistonesHormonesImageImmuneImmune EvasionImmune responseImmune systemImmunofluorescence ImmunologicImmunoprecipitationIncidenceInjectionsInterferon Type IInterferonsInterruptionLesionLigandsMalignant NeoplasmsMammary NeoplasmsMammary glandMass Spectrum AnalysisMediatingMethodsModificationMusNuclear ReceptorsPathway interactionsPatientsPost-Translational Protein ProcessingPrevention therapyProcessProductionProgesteroneProgesterone ReceptorsProgestinsPromoter RegionsProteinsPublic HealthReceptor ActivationRegulationRoleSTAT proteinSignal PathwaySignal TransductionSignaling MoleculeSignaling ProteinTechniquesTestingTherapeuticTimeTranscription CoactivatorTranscription Repressor/CorepressorTumor-Associated ProcessUnited StatesVirus DiseasesWomanattenuationbasebreast cancer progressionbreast lesioncell transformationchromatin immunoprecipitationclinically relevantcofactorcytokineexperimental studygene repressionimmune clearanceimmune system functionimmunological interventionimprovedin vivoinsightinterestknock-downmalignant breast neoplasmmouse modelnovelprogesterone receptor Aprogesterone receptor positivepromoterprotein expressionprotein protein interactionreceptorreceptor expressionreceptor functionrecruitresponsetranscription factortumortumor progressiontumorigenic
中文摘要
摘要
乳腺癌是一种异质性极强的疾病,影响着全球近200万女性。
每年。在这些乳腺肿瘤中,大约70%表达孕激素受体(PR),一种核蛋白
受体和配体激活的转录因子,对黄体酮的反应被激活。引人入胜
临床试验数据表明,孕激素在乳腺癌的发展中起作用,而不依赖于
被广泛研究的雌激素受体。然而,发生这种情况的机制还远未得到充分研究。我们的
实验室利用微阵列数据结合基因集浓缩分析,确定了一种新的基因子集
在PR激活后表达发生变化的基因。这些基因主要参与干扰素信号传递-
一种通常用于应对病毒感染的途径。我们的数据显示,许多正常情况下
当PR被抑制时,对干扰素信号(干扰素刺激基因,ISGs)的反应被激活
被它的配体激活。我们的实验室还表明,当PR表达被瞬间击倒时,ISG
转录抑制丢失,表明这些基因的抑制是PR依赖的。最后,我们有
进行染色质免疫沉淀实验,观察到ISG募集减少
ISG启动子区域的转录机制,证明PR在阻断规范干扰素中的作用
发信号。免疫系统的逃避最近被添加到癌症和我们的
初步数据表明,肿瘤能够逃脱免疫检测的潜在机制。
激活I型干扰素信号是标记肿瘤进行免疫清除的早期步骤,并通过
抑制ISG蛋白的表达,有可能使这些肿瘤逃避免疫检测而导致肿瘤
建立和发展。本文提出的实验旨在阐明
PR抑制典型的干扰素信号和ISG的表达,以及这种抑制如何影响乳腺肿瘤
体内形成和免疫反应。我们将通过确定前者之间的直接交互来解决前者
PR和干扰素信号组件以及使用称为快速的高通量技术
免疫沉淀-质谱法鉴定PR与内源蛋白的相互作用
可能有助于抑制ISG转录的转录辅助因子。然后,我们将通过使用
同基因小鼠模型,允许我们在功能完全正常的情况下观察肿瘤的形成
免疫系统。我们将评估存在和不存在时肿瘤潜伏期和免疫反应的变化
PR和黄体酮。确定PR和孕激素在免疫逃避中的这一新角色提供了洞察力
可以帮助改进现有的仅以雌激素为基础的激素预防和治疗疗法
依赖性乳腺癌。
英文摘要
Abstract
Breast cancer is an extremely heterogeneous disease that affects close to two million women across the globe
each year. Of these breast tumors, approximately 70% express the progesterone receptor (PR), a nuclear
receptor and ligand-activated transcription factor that is activated in response to progesterone. Compelling
clinical trial data have suggested that progestins have a role in breast cancer development, independent of the
widely-studied estrogen receptor. The mechanism by which this occurs, however, is vastly understudied. Our
lab, using microarray data combined with Gene Set Enrichment Analysis, has identified a novel subset of genes
that have altered expression following PR activation. These genes are primarily involved in interferon signaling—
a pathway normally utilized in response to viral infection. Our data show that many genes that are normally
activated in response to interferon signaling (interferon stimulated genes, ISGs) are repressed when PR is
activated by its ligand. Our lab has also shown that when PR expression is transiently knocked down, ISG
transcriptional repression is lost, indicating that the repression of these genes is PR dependent. Finally, we have
performed chromatin immunoprecipitation experiments and observed diminished recruitment of ISG
transcriptional machinery to ISG promoter regions, demonstrating PR's role in interrupting canonical interferon
signaling. Evasion of the immune system has recently been added to the list of Hallmarks of Cancer and our
preliminary data suggest a potential mechanism by which tumors are able to escape immune detection.
Activation of type I interferon signaling is an early step in marking tumors for immune clearance and, by
repressing ISG protein expression, it is possible that these tumors can avoid immune detection leading to tumor
establishment and progression. The experiments proposed herein aim to elucidate the mechanisms by which
PR inhibits canonical interferon signaling and ISG expression, and how this inhibition affects mammary tumor
formation and immune response in vivo. We will address the former by identifying direct interactions between
PR and interferon signaling components as well as use a high throughput technique known as Rapid
Immunoprecipitation Mass Spectrometry of Endogenous Proteins (RIME) to identify PR interactions with
transcriptional cofactors that may aid in inhibiting ISG transcription. We will then address the latter by utilizing a
syngeneic mouse model which allows us to observe tumor formation in the presence of a fully functioning
immune system. We will evaluate changes in tumor latency and immune response in the presence and absence
of PR and progesterone. Determining this novel role of PR and progestins in immune evasion offers insight that
could aid in improving upon established estrogen only-based therapies for prevention and treatment of hormone
dependent breast cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金